MARKET

CYCC

CYCC

Cyclacel Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.37
-0.10
-1.34%
After Hours: 7.29 -0.08 -1.09% 17:49 03/02 EST
OPEN
7.41
PREV CLOSE
7.47
HIGH
7.88
LOW
7.28
VOLUME
187.84K
TURNOVER
--
52 WEEK HIGH
19.25
52 WEEK LOW
3.120
MARKET CAP
39.43M
P/E (TTM)
-1.4003
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
10-K: CYCLACEL PHARMACEUTICALS, INC.
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations Cautionary Statement Regarding...
Edgar Online - (EDG = 10Q, 10K) · 1d ago
DJ Cyclacel Pharmaceuticals, Inc. CEO Spiro Rombotis on Q4 2020 Results -- Earnings Call Transcript >CYCC
Dow Jones · 4d ago
BRIEF-Cyclacel Pharma Reports Q4 And Full Year 2020 Financial Results
reuters.com · 5d ago
Cyclacel Pharmaceuticals EPS misses by $2.21
Cyclacel Pharmaceuticals (CYCC): Q4 GAAP EPS of -$2.74 misses by $2.21.As of December 31, 2020, cash and cash equivalents totaled $33.4 million. Additional proceeds of $4.3 million were received from
Seekingalpha · 5d ago
Cyclacel Pharmaceuticals Q4 EPS $(1.34) Misses $(0.51) Estimate
Cyclacel Pharmaceuticals (NASDAQ:CYCC) reported quarterly losses of $(1.34) per share which missed the analyst consensus estimate of $(0.51) by 162.75 percent. This is a 857.14 percent decrease over losses of $(0.14) per
Benzinga · 5d ago
Cyclacel Pharmaceuticals 4Q Loss/Shr $1.34 >CYCC
Cyclacel Pharmaceuticals 4Q Loss/Shr $1.34 >CYCC
Dow Jones · 5d ago
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
BERKELEY HEIGHTS, N.J., Feb 25, 2021 (GLOBE NEWSWIRE via COMTEX) -- BERKELEY HEIGHTS, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc....
GlobeNewswire · 5d ago
Press Release: Cyclacel Pharmaceuticals Reports -2-
Dow Jones · 5d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CYCC. Analyze the recent business situations of Cyclacel Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CYCC stock price target is 21.33 with a high estimate of 24.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 28
Institutional Holdings: 1.67M
% Owned: 31.29%
Shares Outstanding: 5.35M
TypeInstitutionsShares
Increased
1
11.25K
New
14
1.43M
Decreased
1
2.99K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.09%
Pharmaceuticals & Medical Research
-0.90%
Key Executives
Chairman/Director
David U'Prichard
President/Chief Executive Officer/Director
Spiro Rombotis
Vice Chairman/Director
Christopher Henney
Chief Financial Officer/Chief Operating Officer/Executive Vice President - Finance/Secretary/Director
Paul McBarron
Senior Vice President
Mark Kirschbaum
Vice President
Judy Chiao
Director
Brian Schwartz
Director
Karin Walker
Independent Director
Samuel Barker
Independent Director
Gregory Hradsky
Independent Director
Lloyd Sems
Independent Director
Robert Spiegel
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
05/26/2016
Dividend USD 0.15
07/13/2016
About CYCC
Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors.

Webull offers kinds of Cyclacel Pharmaceuticals Inc stock information, including NASDAQ:CYCC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYCC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CYCC stock methods without spending real money on the virtual paper trading platform.